The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

Prithviraj Bose, MD, provides an overview of the different JAK inhibitors currently available for patients with myeloproliferative neoplasms. Prithviraj Bose, MD, professor in the Department of ...

Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...